Cadence Neuroscience is developing an implantable neuromodulation therapy for pediatric and adult patients with focal drug-resistant epilepsy. The company is based on Mayo Clinic research and sits within the implanted epilepsy neuromodulation segment, alongside established device approaches such as VNS, RNS, and DBS. Its clinical focus is on patients whose seizures remain difficult to control with medication and who may have limited suitability for resective surgery.

The system uses chronic subthreshold cortical stimulation to modulate EEG biomarkers associated with epilepsy. Cadence describes its approach as using established neuromodulation materials and processes, combined with software that supports personalized stimulation based on each patient’s brain activity and response. The approach is designed around ongoing cortical stimulation at individualized settings, rather than seizure-triggered stimulation alone.

Cadence targets clinical epilepsy care settings, where implantation, programming, and follow-up are handled by specialist providers. The company remains investigational and has raised Series B funding to support pivotal clinical studies and pursue FDA clearance. It is best understood as a clinical-stage epilepsy neuromodulation company translating chronic cortical stimulation research into a regulated implantable therapy pathway.